Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03313557 · ClinicalTrials.gov registry record · Phase 1
AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT03313557 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 48 participants.
The verdict
NCT03313557, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
Open-label, non-randomised study to provide continued access to AZD1775 for patients with advanced solid tumours who have previously completed an AZD1775 clinical pharmacology study and to investigate the safety of AZD1775.
Interventions
- DRUG Wee-1 kinase inhibitor AZD1775
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-10-27 |
| Est. Completion | 2019-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03313557
The ClinicalTrials.gov registry entry for NCT03313557 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Wee-1 kinase inhibitor AZD1775 is the first listed.
NCT03313557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03313557 about?
NCT03313557 is a clinical study titled "AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies". Open-label, non-randomised study to provide continued access to AZD1775 for patients with advanced solid tumours who have previously completed an AZD1775 clinical pharmacology study and to investigate the safety of AZD1775.
What is the current status of trial NCT03313557?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2017-10-27. Estimated completion is 2019-05-17.
What interventions are being tested in trial NCT03313557?
The interventions under investigation include: Wee-1 kinase inhibitor AZD1775 (DRUG).
Who is sponsoring clinical trial NCT03313557?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.